SCHEMBL2837335

SCHEMBL2837335

COc1cc(C)c(S(=O)(=O)N2CCCCC2COc2ccnc(N3CCN(CC4CCN(C)CC4)CC3)n2)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 2/20 0.41
HTR2A P28223 2/20 0.36
HTR2C P28335 1/20 0.36
BRAF P15056 4/20 0.35
CASP3 P42574 5/20 0.34
CASP7 P55210 4/20 0.34
CCR4 P51679 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
ELANE P08246 1/20 0.34
EHMT2 Q96KQ7 1/20 0.33
CASP1 P29466 1/20 0.33
CASP4 P49662 1/20 0.33
CASP5 P51878 1/20 0.33
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
HTR7 P34969 1/20 0.33
HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834791 0.98 BDKRB1 (0.41) BDKRB1HTR2AHTR2CBRAFCASP3
SCHEMBL2836548 0.93 CA12 (0.38) CASP3CASP7CCR4CA12CA1
SCHEMBL2832782 0.91 CA12 (0.39) CASP3CASP7CCR4CA12CA1
SCHEMBL2839928 0.90 BDKRB1 (0.39) BDKRB1CA12CA1CA2CA9
SCHEMBL2836786 0.89 KMT2A (0.39) CASP3CASP7CASP1
SCHEMBL2839870 0.88 HTR7 (0.38) HTR2ACASP3CASP7HTR1ADRD2
SCHEMBL2836488 0.88 BDKRB1 (0.40) BDKRB1CASP3CASP7CCR4CA12
SCHEMBL2836552 0.87 HTR7 (0.38) HTR2ACASP3CASP7HTR1ADRD2
SCHEMBL2832996 0.86 KMT2A (0.40) CASP3CASP7CASP1HTR7
SCHEMBL2835399 0.86 HTR2A (0.41) BDKRB1HTR2AHTR2CBRAFCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS BDKRB1 46/4885HTR2A 256/4885HTR2C 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.